POLÍTICAS DE CANNABIS: GENERALIDADES

Fuente: PubMed [Internet]. Bethesda (MD): US National Library of Medicine National Institutes of Health; [consulta 25 mayo 2022]. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/

Detalles de búsqueda: ("Cannabis policy"[All Fields]) AND (y_5[Filter])

2022

Philbin MM, Giovenco DP, Mauro PM. Commentary on Weinberger et al.: Tobacco and cannabis policies as drivers of nicotine and cannabis co-use - research and measurement implications to move the field forward. Addiction. junio de 2022;117(6):1778-80.

Goodman S, Wadsworth E, Hammond D. Reasons for Purchasing Cannabis From Illegal Sources in Legal Markets: Findings Among Cannabis Consumers in Canada and U.S. States, 2019-2020. J Stud Alcohol Drugs. mayo de 2022;83(3):392-401.

Goodman S, Hammond D. Perceptions of the health risks of cannabis: estimates from national surveys in Canada and the United States, 2018-2019. Health Educ Res. 24 de marzo de 2022;37(2):61-78.

Pacula RL, Smart R, Lira MC, Pessar SC, Blanchette JG, Naimi TS. Relationships of Cannabis Policy Liberalization With Alcohol Use and Co-Use With Cannabis: A Narrative Review. Alcohol Res. 2022;42(1):06.

Kitchen C, Kabba JA, Fang Y. Status and Impacts of Recreational and Medicinal Cannabis Policies in Africa: A Systematic Review and Thematic Analysis of Published and «Gray» Literature. Cannabis Cannabinoid Res. 5 de enero de 2022;

Gabri AC, Galanti MR, Orsini N, Magnusson C. Changes in cannabis policy and prevalence of recreational cannabis use among adolescents and young adults in Europe-An interrupted time-series analysis. PLoS One. 2022;17(1):e0261885.

2021

Schauer GL. Cannabis Policy in the United States: Implications for Public Health. J Natl Cancer Inst Monogr. 28 de noviembre de 2021;2021(58):39-52.

Crépault J-F, Rehm J, Room R. Legalization as more effective control? Parallels between the end of alcohol prohibition (1927) and the legalization of cannabis (2018) in Ontario, Canada. Int J Drug Policy. noviembre de 2021;97:103367.

Calvert CM, Erickson D. Recreational cannabis legalization and alcohol purchasing: a difference-in-differences analysis. J Cannabis Res. 7 de julio de 2021;3(1):27.

Monaghan M, Wincup E, Hamilton I. Scandalous decisions: explaining shifts in UK medicinal cannabis policy. Addiction. julio de 2021;116(7):1925-33.

Benedetti E, Resce G, Brunori P, Molinaro S. Cannabis Policy Changes and Adolescent Cannabis Use: Evidence from Europe. Int J Environ Res Public Health. 13 de mayo de 2021;18(10):5174.

Ryan JE, McCabe SE, Boyd CJ. Medicinal Cannabis: Policy, Patients, and Providers. Policy Polit Nurs Pract. mayo de 2021;22(2):126-33.

Obradovic I. From prohibition to regulation: A comparative analysis of the emergence and related outcomes of new legal cannabis policy models (Colorado, Washington State and Uruguay). Int J Drug Policy. mayo de 2021;91:102590.

Johnson JK, Doonan SM. Cannabis Policy Heterogeneity and Effects on Research-Complexity Expected. JAMA Netw Open. 1 de marzo de 2021;4(3):e212545.

Fischer B, Hall W. New Zealand's failed cannabis legalization referendum - implications for cannabis policy reform. Lancet Reg Health West Pac. febrero de 2021;7:100080.

Kim JH, Weinberger AH, Zhu J, Barrington-Trimis J, Wyka K, Goodwin RD. Impact of state-level cannabis legalization on poly use of alcohol and cannabis in the United States, 2004-2017. Drug Alcohol Depend. 1 de enero de 2021;218:108364.

Fataar F, Goodman S, Wadsworth E, Hammond D. Consumer perceptions of «legal» and «illegal» cannabis in US states with legal cannabis sales. Addict Behav. enero de 2021;112:106563.

López-Pelayo H, Matrai S, Balcells-Olivero M, Campeny E, Braddick F, Bossong MG, et al. Supporting Future Cannabis Policy - Developing a Standard Joint Unit: A Brief Back-Casting Exercise. Front Psychiatry. 2021;12:675033.

2020

Areesantichai C, Perngparn U, Pilley C. Current cannabis-related situation in the Asia-Pacific region. Curr Opin Psychiatry. julio de 2020;33(4):352-9.

Trangenstein PJ. Social Bots Likely Pose an Undue Influence to Cannabis Policy. Am J Public Health. marzo de 2020;110(3):264-5.

2019

Rehm J, Elton-Marshall T, Sornpaisarn B, Manthey J. Medical marijuana. What can we learn from the experiences in Canada, Germany and Thailand? Int J Drug Policy. diciembre de 2019;74:47-51.

Bowling C, Glantz SA. Civic Engagement in California Cannabis Policy Development. J Psychoactive Drugs. diciembre de 2019;51(5):391-9.

Chow RM, Marascalchi B, Abrams WB, Peiris NA, Odonkor CA, Cohen SP. Driving Under the Influence of Cannabis: A Framework for Future Policy. Anesth Analg. junio de 2019;128(6):1300-8.

Stevens A. Is policy «liberalization» associated with higher odds of adolescent cannabis use? A re-analysis of data from 38 countries. Int J Drug Policy. abril de 2019;66:94-9.

Smart R, Pacula RL. Early evidence of the impact of cannabis legalization on cannabis use, cannabis use disorder, and the use of other substances: Findings from state policy evaluations. Am J Drug Alcohol Abuse. 2019;45(6):644-63.

Shover CL, Humphreys K. Six policy lessons relevant to cannabis legalization. Am J Drug Alcohol Abuse. 2019;45(6):698-706.

Arora K, Qualls SH, Bobitt J, Lum HD, Milavetz G, Croker J, et al. Measuring Attitudes Toward Medical and Recreational Cannabis Among Older Adults in Colorado. Gerontologist. 14 de mayo de 2019;

Belackova V, Roubalova Stefunkova M, van de Ven K. Overview of «home» cultivation policies and the case for community-based cannabis supply. Int J Drug Policy. 11 de junio de 2019;71:36-46.

Bowling C, Glantz SA. Civic Engagement in California Cannabis Policy Development. J Psychoactive Drugs. 12 de junio de 2019;

Chow RM, Marascalchi B, Abrams WB, Peiris NA, Odonkor CA, Cohen SP. Driving Under the Influence of Cannabis: A Framework for Future Policy. Anesth Analg. junio de 2019;128(6):1300-8.

Gonzalez M, Sanders-Jackson A, Henriksen L. Social Capital and Tobacco Retail Outlet Density: An Empirical Test of the Relationship. Am J Health Promot. septiembre de 2019;33(7):1020-7.

Goodman S, Leos-Toro C, Hammond D. Methods to Assess Cannabis Consumption in Population Surveys: Results of Cognitive Interviewing. Qual Health Res. agosto de 2019;29(10):1474-82.

Goodman S, Leos-Toro C, Hammond D. Methods to Assess Cannabis Consumption in Population Surveys: Results of Cognitive Interviewing. Qual Health Res. 2 de enero de 2019;1049732318820523.

Haines-Saah RJ, Mitchell S, Slemon A, Jenkins EK. «Parents are the best prevention»? Troubling

assumptions in cannabis policy and prevention discourses in the context of legalization in Canada. Int J Drug Policy. junio de 2019;68:132-8.

Kotlaja MM, Carson JV. Cannabis Prevalence and National Drug Policy in 27 Countries: An Analysis of Adolescent Substance Use. Int J Offender Ther Comp Criminol. mayo de 2019;63(7):1082-99.

Melchior M, Nakamura A, Bolze C, Hausfater F, El Khoury F, Mary-Krause M, et al. Does liberalisation of cannabis policy influence levels of use in adolescents and young adults? A systematic review and meta-analysis. BMJ Open. 10 de julio de 2019;9(7):e025880.

Resko S, Ellis J, Early TJ, Szechy KA, Rodriguez B, Agius E. Understanding Public Attitudes Toward Cannabis Legalization: Qualitative Findings From a Statewide Survey. Subst Use Misuse. 19 de abril de 2019;1-13.

Shover CL, Humphreys K. Six policy lessons relevant to cannabis legalization. Am J Drug Alcohol Abuse. 14 de marzo de 2019;1-9.

Stevens A. Is policy «liberalization» associated with higher odds of adolescent cannabis use? A re-analysis of data from 38 countries. Int J Drug Policy. abril de 2019;66:94-9.

2018

Belackova V, Wilkins C. Consumer agency in cannabis supply - Exploring auto-regulatory documents of the cannabis social clubs in Spain. Int J Drug Policy. 2018;54:26-34.

Blevins CE, Marsh E, Banes KE, Stephens RS, Walker DD, Roffman RA. The Implications of Cannabis Policy Changes in Washington on Adolescent Perception of Risk, Norms, Attitudes, and Substance Use. Subst Abuse. 2018;12:1178221818815491.

Chow RM, Marascalchi B, Abrams WB, Peiris NA, Odonkor CA, Cohen SP. Driving Under the Influence of Cannabis: A Framework for Future Policy. Anesth Analg. 20 de junio de 2018.

Haines-Saah RJ, Mitchell S, Slemon A, Jenkins EK. «Parents are the best prevention»? Troubling assumptions in cannabis policy and prevention discourses in the context of legalization in Canada. Int J Drug Policy. 17 de julio de 2018.

Hall W, West R, Marsden J, Humphreys K, Neale JO, Petry N. The need for more consistent evidential standards in cannabis policy evaluations. Addiction. agosto de 2018;113(8):1553-4.

Hughes B, Wiessing L, Des Jarlais D, Griffiths P. Could cannabis liberalisation lead to wider changes in drug policies and outcomes? Int J Drug Policy. 2018;51:156-9.

Hughes CE. The trajectories of cannabis and tobacco policies in the United States, Uruguay, Canada

and Portugal: is more cross-substance learning possible outside the United States? Addiction. abril de 2018;113(4):603-5.

Neu P. [Discussing possible new regulations in german cannabis policy with special regard to the experiences in the Netherlands and Colorado]. Fortschr Neurol Psychiatr. 2018;86(7):428-33.

Pardal M. An analysis of Belgian Cannabis Social Clubs' supply practices: A shapeshifting model? Int J Drug Policy. 2018;57:32-41.

Rogeberg O. Prohibition, regulation or laissez faire: The policy trade-offs of cannabis policy. Int J Drug Policy. 2018;56:153-61.

Rolles S. The different outcomes of legislative- versus advocacy-led development of cannabis policy. Addiction. abril de 2018;113(4):606-7.

Skliamis K, Korf DJ. An Exploratory Study of Cannabis Festivals and Their Attendees in Two European Cities: Amsterdam and Berlin. J Psychoactive Drugs. junio de 2018;50(2):105-13.

Zarhin D, Negev M, Vulfsons S, Sznitman SR. Rhetorical and regulatory boundary-work: The case of medical cannabis policy-making in Israel. Soc Sci Med. noviembre de 2018;217:1-9.

2017

Adam C, Raschzok A. Cannabis policy and the uptake of treatment for cannabis-related problems. Drug Alcohol Rev. 2017;36(2):171-7.

Alshaarawy O, Anthony JC. The replicability of cannabis use prevalence estimates in the United States. Int J Methods Psychiatr Res. 2017;26(2).

Budney AJ, Borodovsky JT. The potential impact of cannabis legalization on the development of cannabis use disorders. Prev Med. noviembre de 2017;104:31-6.

Cambron C, Guttmannova K, Fleming CB. State and National Contexts in Evaluating Cannabis Laws: A Case Study of Washington State. J Drug Issues. enero de 2017;47(1):74-90.

Červený J, Chomynová P, Mravčík V, van Ours JC. Cannabis decriminalization and the age of onset of cannabis use. Int J Drug Policy. 2017;43:122-9.

Chatwin C. UNGASS 2016: Insights from Europe on the development of global cannabis policy and the need for reform of the global drug policy regime. Int J Drug Policy. 2017;49:80-5.

Decorte T, Pardal M, Queirolo R, Boidi MF, Sánchez Avilés C, Parés Franquero Ò. Regulating Cannabis Social Clubs: A comparative analysis of legal and self-regulatory practices in Spain,

Belgium and Uruguay. Int J Drug Policy. 2017;43:44-56.

Gourdet C, Giombi KC, Kosa K, Wiley J, Cates S. How four U.S. states are regulating recreational marijuana edibles. Int J Drug Policy. 2017;43:83-90.

Grbic J, Goddard P, Ryder D. Observations of the role of science in the United States medical cannabis state policies: Lessons learnt. Int J Drug Policy. 2017;42:109-14.

Klitzner MD, Thomas S, Schuler J, Hilton M, Mosher J. The New Cannabis Policy Taxonomy on APIS: Making Sense of the Cannabis Policy Universe. J Prim Prev. junio de 2017;38(3):295-314.

Lancaster K, Seear K, Ritter A. Making medicine; producing pleasure: A critical examination of medicinal cannabis policy and law in Victoria, Australia. Int J Drug Policy. 2017;49:117-25.

Mendiburo-Seguel A, Vargas S, Oyanedel JC, Torres F, Vergara E, Hough M. Attitudes towards drug policies in Latin America: Results from a Latin-American Survey. Int J Drug Policy. 2017;41:8-13.

Stevens A, Pacula RL. Advancing knowledge on cannabis policy using evidence from North America. Int J Drug Policy. 2017;42:36-8.

Weiss SRB, Howlett KD, Baler RD. Building smart cannabis policy from the science up. Int J Drug Policy. 2017;42:39-49.

2016

Sznitman SR, Taubman DS. Drug Use Normalization: A Systematic and Critical Mixed-Methods Review. J Stud Alcohol Drugs. 2016;77(5):700-9.

Kirst M, Kolar K, Chaiton M, Schwartz R, Emerson B, Hyshka E, et al. A common public health-oriented policy framework for cannabis, alcohol and tobacco in Canada? Can J Public Health. 16 de marzo de 2016;106(8):e474-476.

Kalant H. A critique of cannabis legalization proposals in Canada. Int J Drug Policy. 2016;34:5-10.

Fischer B, Rehm J, Crépault J-F. Realistically furthering the goals of public health by cannabis legalization with strict regulation: Response to Kalant. Int J Drug Policy. agosto de 2016;34:11-6.

Dirisu O, Shickle D, Elsey H. Influence of legal status on the uptake of cannabis in young people. Curr Opin Psychiatry. 2016;29(4):231-5.

Crépault J-F, Rehm J, Fischer B. The Cannabis Policy Framework by the Centre for Addiction and Mental Health: A proposal for a public health approach to cannabis policy in Canada. Int J Drug Policy. 2016;34:1-4.

Bretteville-Jensen AL. Expected lessons from the US experience with alternative cannabis policy regimes. Addiction. 2016;111(12):2090-1.

Alvarez A, Gamella JF, Parra I. Cannabis cultivation in Spain: A profile of plantations, growers and production systems. Int J Drug Policy. 2016;37:70-81.

Stein DJ. Position statement on cannabis. S Afr Med J. 16 de 2016;106(6):45-6.

2015

Belackova V, Maalsté N, Zabransky T, Grund JP. «Should I Buy or Should I Grow?» How drug policy institutions and drug market transaction costs shape the decision to self-supply with cannabis in the Netherlands and the Czech Republic. Int J Drug Policy. marzo de 2015;26(3):296-310.

Decorte T. Cannabis social clubs in Belgium: organizational strengths and weaknesses, and threats to the model. Int J Drug Policy. febrero de 2015;26(2):122-30.

Fergusson DM, Boden JM, Horwood LJ. Psychosocial sequelae of cannabis use and implications for policy: findings from the Christchurch Health and Development Study. Soc Psychiatry Psychiatr Epidemiol. septiembre de 2015;50(9):1317-26.

Hall W. Getting to grips with the cannabis problem: the evolving contributions and impact of Griffith Edwards. Addiction. julio de 2015;110 Suppl 2:36-9.

Ogrodnik M, Kopp P, Bongaerts X, Tecco JM. An economic analysis of different cannabis decriminalization scenarios. Psychiatr Danub. septiembre de 2015;27 Suppl 1:S309-314.

Ramo DE, Popova L, Grana R, Zhao S, Chavez K. Cannabis Mobile Apps: A Content Analysis. JMIR Mhealth Uhealth. 12 de agosto de 2015;3(3):e81.

Sachs J, McGlade E, Yurgelun-Todd D. Safety and Toxicology of Cannabinoids. Neurotherapeutics. octubre de 2015;12(4):735-46.

Sznitman SR, Bretteville-Jensen AL. Public opinion and medical cannabis policies: examining the role of underlying beliefs and national medical cannabis policies. Harm Reduct J. 14 de octubre de 2015;12:46.

Sznitman SR, Lewis N. Is cannabis an illicit drug or a medicine? A quantitative framing analysis of Israeli newspaper coverage. Int J Drug Policy. mayo de 2015;26(5):446-52.

2014

Hall W. Robin Room and cannabis policy: dangerous comparisons. Drug Alcohol Rev. noviembre

de 2014;33(6):612-6.

Kilmer B. Policy designs for cannabis legalization: starting with the eight Ps. Am J Drug Alcohol Abuse. julio de 2014;40(4):259-61.

Månsson J. A dawning demand for a new cannabis policy: A study of Swedish online drug discussions. Int J Drug Policy. julio de 2014;25(4):673-81.

Pardo B. Cannabis policy reforms in the Americas: a comparative analysis of Colorado, Washington, and Uruguay. Int J Drug Policy. julio de 2014;25(4):727-35.

Shanahan M, Gerard K, Ritter A. Preferences for policy options for cannabis in an Australian general population: A discrete choice experiment. Int J Drug Policy. julio de 2014;25(4):682-90.

Williams J, Bretteville-Jensen AL. Does liberalizing cannabis laws increase cannabis use? J Health Econ. julio de 2014;36:20-32.

CANNABIS: REGULACIÓN Y POLÍTICAS DE DROGAS

Fuente: PubMed [Internet]. Bethesda (MD): US National Library of Medicine National Institutes of Health; [consulta 25 mayo 2022]. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/

Detalles de búsqueda: ((("cannabis"[MeSH Terms] OR "cannabis"[All Fields]) AND ("legal"[All Fields] OR "legalism"[All Fields] OR "legalities"[All Fields] OR "legality"[All Fields] OR "legalization"[All Fields] OR "legalize"[All Fields] OR "legalized"[All Fields] OR "legalizes"[All Fields] OR "legalizing"[All Fields] OR "legally"[All Fields]) AND "drug policy"[All Fields]) NOT ("economics"[MeSH Subheading] OR "economics"[All Fields] OR "economics"[MeSH Terms])) AND (y_5[Filter])

2022

Ventresca M, Elliott C. Cannabis edibles packaging: Communicative objects in a growing market. Int J Drug Policy. mayo de 2022;103:103645.

Lazor T, Blondal E, Scheim A, Cubillos P, Werb D, Milloy M-J, et al. Measurement of public health impacts of cannabis legalization in Canada to reflect policy maker priorities: A rapid scoping review of instruments and content domains. Drug Alcohol Depend. 15 de abril de 2022;236:109463.

Kilmer B, Rivera-Aguirre A, Queirolo R, Ramirez J, Cerdá M. Cannabis legalization and traffic injuries: exploring the role of supply mechanisms. Addiction. 7 de febrero de 2022;

Wu G, Li Y, Eric Lang X. Effects of recreational marijuana legalization on clearance rates for violent crimes: Evidence from Oregon. Int J Drug Policy. febrero de 2022;100:103528.

Vann B. Direct democracy and the adoption of recreational marijuana legalization in the United States, 2012-2019. Int J Drug Policy. 4 de febrero de 2022;102:103583.

Okey SA, Castro SA, Waddell JT, Jones CB, Blake AJ, O'Rourke HP, et al. Are recreational cannabis laws associated with declining medical cannabis program enrollment in the U.S.? An analysis of cardholder enrollment and demographic characteristics from 2013 to 2020. Int J Drug Policy. febrero de 2022;100:103531.

Espinosa S, Marks C, Fondevila G. Identifying archetypal cannabis consumers to inform drug policy design: a Q-sort assessment of young adults' attitudes in Mexico City's metropolitan area. J Cannabis Res. 8 de enero de 2022;4(1):5.

2021

Bourdon JL, Francis MW, Jia L, Liang C, Robinson HI, Grucza RA. The effect of cannabis policies on

treatment outcomes for cannabis use among U.S. adults. J Subst Abuse Treat. diciembre de 2021;131:108535.

Leas EC, Nobles AL, Shi Y, Hendrickson E. Public interest in Δ8-Tetrahydrocannabinol (delta-8-THC) increased in US states that restricted Δ9-Tetrahydrocannabinol (delta-9-THC) use. Int J Drug Policy. 21 de diciembre de 2021;101:103557.

Quednow BB, Steinhoff A, Bechtiger L, Ribeaud D, Eisner M, Shanahan L. High Prevalence and Early Onsets: Legal and Illegal Substance Use in an Urban Cohort of Young Adults in Switzerland. Eur Addict Res. 3 de diciembre de 2021;1-13.

Qatanani A, Umar M, Padela AI. Bioethical insights from the Fiqh Council of North America's recent ruling on medical cannabis. Int J Drug Policy. noviembre de 2021;97:103360.

Perkins D, Brophy H, McGregor IS, O'Brien P, Quilter J, McNamara L, et al. Medicinal cannabis and driving: the intersection of health and road safety policy. Int J Drug Policy. noviembre de 2021;97:103307.

Crépault J-F, Rehm J, Room R. Legalization as more effective control? Parallels between the end of alcohol prohibition (1927) and the legalization of cannabis (2018) in Ontario, Canada. Int J Drug Policy. noviembre de 2021;97:103367.

Adams PJ, Rychert M, Wilkins C. Policy influence and the legalized cannabis industry: learnings from other addictive consumption industries. Addiction. noviembre de 2021;116(11):2939-46.

Adams PJ, Rychert M, Wilkins C. How does the influence of the cannabis industry differ from that of alcohol and tobacco? Addiction. noviembre de 2021;116(11):2951-2.

Goundar P, Macaulay T, Szafron M. A comparative analysis of laws on recreational cannabis edibles between Canada and the United States of America. Int J Drug Policy. agosto de 2021;94:103191.

Caulkins JP. Radical technological breakthroughs in drugs and drug markets: The cases of cannabis and fentanyl. Int J Drug Policy. agosto de 2021;94:103162.

Winstock AR, Lynskey MT, Maier LJ, Ferris JA, Davies EL. Perceptions of cannabis health information labels among people who use cannabis in the U.S. and Canada. Int J Drug Policy. mayo de 2021;91:102789.

Obradovic I. From prohibition to regulation: A comparative analysis of the emergence and related outcomes of new legal cannabis policy models (Colorado, Washington State and Uruguay). Int J Drug Policy. mayo de 2021;91:102590.

Boyd N, Sevigny EL. Strategic innovations in cannabis legalization policy: Lessons from early

adopters. Int J Drug Policy. mayo de 2021;91:103193.

2020

Fink DS, Stohl M, Sarvet AL, Cerdà M, Keyes KM, Hasin DS. Medical marijuana laws and driving under the influence of marijuana and alcohol. Addiction. octubre de 2020;115(10):1944-53.

Scheim AI, Maghsoudi N, Marshall Z, Churchill S, Ziegler C, Werb D. Impact evaluations of drug decriminalisation and legal regulation on drug use, health and social harms: a systematic review. BMJ Open. 21 de septiembre de 2020;10(9):e035148.

Santaella-Tenorio J, Wheeler-Martin K, DiMaggio CJ, Castillo-Carniglia A, Keyes KM, Hasin D, Cerdà M. Association of Recreational Cannabis Laws in Colorado and Washington State With Changes in Traffic Fatalities, 2005-2017. JAMA Intern Med. 1 de agosto de 2020;180(8):1061-8.

Laqueur H, Rivera-Aguirre A, Shev A, Castillo-Carniglia A, Rudolph KE, Ramirez J, et al. The impact of cannabis legalization in Uruguay on adolescent cannabis use. Int J Drug Policy. junio de 2020;80:102748.

Takakuwa KM. A history of the Society of Cannabis Clinicians and its contributions and impact on the US medical cannabis movement. Int J Drug Policy. 11 de abril de 2020;79:102749.

Hammond D, Goodman S, Wadsworth E, Rynard V, Boudreau C, Hall W. Evaluating the impacts of cannabis legalization: The International Cannabis Policy Study. Int J Drug Policy. 26 de febrero de 2020;77:102698.

Fischer B, Bullen C. Emerging prospects for non-medical cannabis legalisation in New Zealand: An initial view and contextualization. Int J Drug Policy. febrero de 2020;76:102632.

Greer A, Ritter A. The legal regulation of drugs and role of government: Perspectives from people who use drugs. Drug Alcohol Depend. 1 de enero de 2020;206:107737.

Frendreis J, Tatalovich R. Postmaterialism and referenda voting to legalize marijuana. Int J Drug Policy. enero de 2020;75:102595.

Midgette G, Reuter P. Has Cannabis Use Among Youth Increased After Changes in Its Legal Status? A Commentary on Use of Monitoring the Future for Analyses of Changes in State Cannabis Laws. Prev Sci. enero de 2020;21(1):137-45.

2019

Gagnon M, Guta A. Cannabis legalization in Canada: What are the potential implications and barriers for people living with HIV? Int J Drug Policy. diciembre de 2019;74:191-2.

Smart R, Pacula RL. Early evidence of the impact of cannabis legalization on cannabis use, cannabis use disorder, and the use of other substances: Findings from state policy evaluations. Am J Drug Alcohol Abuse. 2019;45(6):644-63.

Melchior M, Nakamura A, Bolze C, Hausfater F, El Khoury F, Mary-Krause M, et al. Does liberalisation of cannabis policy influence levels of use in adolescents and young adults? A systematic review and meta-analysis. BMJ Open. 10 de julio de 2019;9(7):e025880.

Caulkins JP, Davenport S, Doanvo A, Furlong K, Siddique A, Turner M, et al. Triangulating web & general population surveys: Do results match legal cannabis market sales? Int J Drug Policy. 1 de julio de 2019;

Caulkins JP, Kilborn ML. Cannabis legalization, regulation, & control: a review of key challenges for local, state, and provincial officials. Am J Drug Alcohol Abuse. 28 de mayo de 2019;1-9.

Chihuri S, Li G. State marijuana laws and opioid overdose mortality. Inj Epidemiol. 2019;6:38.

Kilmer B. How will cannabis legalization affect health, safety, and social equity outcomes? It largely depends on the 14 Ps. Am J Drug Alcohol Abuse. 2 de julio de 2019;1-9.

Mahamad S, Hammond D. Retail price and availability of illicit cannabis in Canada. Addict Behav. marzo de 2019;90:402-8.

Wadsworth E, Hammond D. International differences in patterns of cannabis use among youth: Prevalence, perceptions of harm, and driving under the influence in Canada, England & United States. Addict Behav. marzo de 2019;90:171-5.

Watson TM, Hyshka E, Bonato S, Rueda S. Early-Stage Cannabis Regulatory Policy Planning Across Canada's Four Largest Provinces: A Descriptive Overview. Subst Use Misuse. 2019;54(10):1691-704.

2018

Bewley-Taylor DR. Canada, cannabis legalization and uncertainty around the United Nations drug control conventions. Addiction. julio de 2018;113(7):1226-8.

Caulkins JP, Bao Y, Davenport S, Fahli I, Guo Y, Kinnard K, et al. Big data on a big new market: Insights from Washington State's legal cannabis market. Int J Drug Policy. 2018;57:86-94.

Caulkins JP. In praise of flawed treaties. Addiction. julio de 2018;113(7):1224-5.

Cox C. The Canadian Cannabis Act legalizes and regulates recreational cannabis use in 2018. Health Policy. 2018;122(3):205-9.

Crépault J-F. Cannabis Legalization in Canada: Reflections on Public Health and the Governance of Legal Psychoactive Substances. Front Public Health. 2018;6:220.

George TP, Hill KP, Vaccarino FJ. Cannabis Legalization and Psychiatric Disorders: Caveat «Hemp-tor». Can J Psychiatry. 2018;63(7):447-50.

Hall W. Imperfect international treaties interpreted flexibly are likely to be better than no treaties. Addiction. julio de 2018;113(7):1230.

Rolles S. The different outcomes of legislative- versus advocacy-led development of cannabis policy. Addiction. abril de 2018;113(4):606-7.

2017

Bear D. From Toques to Tokes: Two challenges facing nationwide legalization of cannabis in Canada. Int J Drug Policy. 2017;42:97-101.

Borodovsky JT, Budney AJ. Legal cannabis laws, home cultivation, and use of edible cannabis products: A growing relationship? Int J Drug Policy. 2017;50:102-10.

Carlini BH. Potency increase, product development and marijuana marketing in times of legalization. Addiction. 2017;112(12):2178-9.

Cerdà M, Kilmer B. Uruguay's middle-ground approach to cannabis legalization. Int J Drug Policy. 2017;42:118-20.

Gourdet C, Giombi KC, Kosa K, Wiley J, Cates S. How four U.S. states are regulating recreational marijuana edibles. Int J Drug Policy. 2017;43:83-90.

Havemann-Reinecke U, Hoch E, Preuss UW, Kiefer F, Batra A, Gerlinger G, et al. [On the legalization debate of non-medical cannabis consumption : Position paper of the German Association for Psychiatry, Psychotherapy and Psychosomatics]. Nervenarzt. marzo de 2017;88(3):291-8.

Kilmer B, Pacula RL. Building the data infrastructure to evaluate cannabis legalization. Addiction. 2017;112(7):1140-1.

Kilmer B, Pacula RL. Understanding and learning from the diversification of cannabis supply laws. Addiction. julio de 2017;112(7):1128-35.

Kilmer B. Recreational Cannabis - Minimizing the Health Risks from Legalization. N Engl J Med. 23 de febrero de 2017;376(8):705-7.

Mark K, Terplan M. Cannabis and pregnancy: Maternal child health implications during a period of

drug policy liberalization. Prev Med. noviembre de 2017;104:46-9.

Mendiburo-Seguel A, Vargas S, Oyanedel JC, Torres F, Vergara E, Hough M. Attitudes towards drug policies in Latin America: Results from a Latin-American Survey. Int J Drug Policy. 2017;41:8-13.

Smart R, Caulkins JP, Kilmer B, Davenport S, Midgette G. Variation in cannabis potency and prices in a newly legal market: evidence from 30 million cannabis sales in Washington state. Addiction. diciembre de 2017;112(12):2167-77.

2016

Bretteville-Jensen AL. Expected lessons from the US experience with alternative cannabis policy regimes. Addiction. 2016;111(12):2090-1.

Caulkins JP, Kilmer B. Considering marijuana legalization carefully: insights for other jurisdictions from analysis for Vermont. Addiction. 2016;111(12):2082-9.

Caulkins JP, Kilmer B. The US as an example of how not to legalize marijuana? Addiction. 2016;111(12):2095-6.

Hajizadeh M. Legalizing and Regulating Marijuana in Canada: Review of Potential Economic, Social, and Health Impacts. Int J Health Policy Manag. 25 de mayo de 2016;5(8):453-6.

Kalant H. A critique of cannabis legalization proposals in Canada. Int J Drug Policy. 2016;34:5-10.

Pacula RL, Jacobson M, Maksabedian EJ. In the weeds: a baseline view of cannabis use among legalizing states and their neighbours. Addiction. 2016;111(6):973-80.

von Hoffmann J. The international dimension of drug policy reform in Uruguay. Int J Drug Policy. 2016;34:27-33.

2015

Rehm J, Fischer B. Cannabis legalization with strict regulation, the overall superior policy option for public health. Clin Pharmacol Ther. junio de 2015;97(6):541-4.

2014

Kilmer B. Policy designs for cannabis legalization: starting with the eight Ps. Am J Drug Alcohol Abuse. julio de 2014;40(4):259-61.

Palamar JJ. An examination of opinions toward marijuana policies among high school seniors in

the United States. J Psychoactive Drugs. diciembre de 2014;46(5):351-61.

CANNABIS: REGULACIÓN Y ASPECTOS ECONÓMICOS

Fuente: PubMed [Internet]. Bethesda (MD): US National Library of Medicine National Institutes of Health; [consulta 25 mayo 2022]. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/

Detalles de búsqueda: ((("cannabis"[MeSH Terms] OR "cannabis"[All Fields]) AND ("legal"[All Fields] OR "legalism"[All Fields] OR "legalities"[All Fields] OR "legality"[All Fields] OR "legalization"[All Fields] OR "legalize"[All Fields] OR "legalized"[All Fields] OR "legalizes"[All Fields] OR "legalizing"[All Fields] OR "legally"[All Fields]) AND ("Cost-Benefit Analysis"[MeSH Terms] OR ("economics"[MeSH Subheading] OR "economics"[All Fields] OR "economics"[MeSH Terms]))) NOT "drug policy"[All Fields]) AND (y_5[Filter])

2022

Pereira-Morales AJ, Eslava-Schmalbach JH. Do alcohol and cannabis substitute or complement each other? Analysis from behavioral economics for formulating public policy on substance use in Colombia. Transl Behav Med. 24 de mayo de 2022;ibac038.

Reed DD, Strickland JC, Gelino BW, Hursh SR, Jarmolowicz DP, Kaplan BA, et al. Applied behavioral economics and public health policies: Historical precedence and translational promise. Behav Processes. mayo de 2022;198:104640.

El-Khoury J, Bou Khalil R, Nemer A, Richa S. Legalizing Medical Cannabis in Lebanon: the Complex Interface Between Medicine, Law, Ethics, and Economics. Cannabis Cannabinoid Res. abril de 2022;7(2):119-21.

Wang GS, Buttorff C, Wilks A, Schwam D, Tung GJ, Banerji S, et al. Comparison of hospital claims and poison center data to evaluate health impact of opioids, cannabis and synthetic cannabinoids. Am J Emerg Med. marzo de 2022;53:150-3.

Wadsworth E, Driezen P, Pacula RL, Hammond D. Cannabis flower prices and transitions to legal sources after legalization in Canada, 2019-2020. Drug Alcohol Depend. 1 de febrero de 2022;231:109262.

2021

Howard J, Wurzelbacher S, Osborne J, Wolf J, Ruser J, Chadarevian R. Review of cannabis reimbursement by workers' compensation insurance in the U.S. and Canada. Am J Ind Med. diciembre de 2021;64(12):989-1001.

Ferguson E, Bush N, Yurasek A, Boissoneault J. The effect of next day responsibilities and an adaptive purchase task on cannabis demand. Drug Alcohol Depend. 1 de octubre de 2021;227:108919.

Erku D, Shrestha S, Scuffham P. Cost-Effectiveness of Medicinal Cannabis for Management of Refractory Symptoms Associated With Chronic Conditions: A Systematic Review of Economic Evaluations. Value Health. octubre de 2021;24(10):1520-30.

Chiu V, Leung J, Hall W, Stjepanović D, Degenhardt L. Public health impacts to date of the legalisation of medical and recreational cannabis use in the USA. Neuropharmacology. 1 de agosto de 2021;193:108610.

Armstrong MJ. Legal cannabis market shares during Canada's first year of recreational legalisation. Int J Drug Policy. febrero de 2021;88:103028.

Davenport S. Price and product variation in Washington's recreational cannabis market. Int J Drug Policy. mayo de 2021;91:102547.

2020

Hall W. The costs and benefits of cannabis control policies. Dialogues Clin Neurosci. septiembre de 2020;22(3):281-7.

2019

Sheridan Rains L, Marston L, Hinton M, Marwaha S, Craig T, Fowler D, et al. Clinical and cost-effectiveness of contingency management for cannabis use in early psychosis: the CIRCLE randomised clinical trial. BMC Med. 15 de agosto de 2019;17(1):161.

Tyree GA, Sarkar R, Bellows BK, Ellis RJ, Atkinson JH, Marcotte TD, et al. A Cost-Effectiveness Model for Adjunctive Smoked Cannabis in the Treatment of Chronic Neuropathic Pain. Cannabis Cannabinoid Res. 2019;4(1):62-72.

Zimmermann K, Kendrick KM, Scheele D, Dau W, Banger M, Maier W, et al. Altered striatal reward processing in abstinent dependent cannabis users: Social context matters. Eur Neuropsychopharmacol. 2019;29(3):356-64.

McCoy MS. Addressing the Conflicts of Interest of Public Officials and Employees: Lessons From Cannabis Legalization. Am J Public Health. marzo de 2019;109(3):350-1.

Amlung M, Reed DD, Morris V, Aston ER, Metrik J, MacKillop J. Price elasticity of illegal versus legal cannabis: a behavioral economic substitutability analysis. Addiction. enero de 2019;114(1):112-8.

Amlung M, MacKillop J. Availability of legalized cannabis reduces demand for illegal cannabis among Canadian cannabis users: evidence from a behavioural economic substitution paradigm. Can J Public Health. abril de 2019;110(2):216-21.

2018

Caldicott D, Sinclair J, Sheridan L, Eckermann S. Medicinal Cannabis and the Tyranny of Distance: Policy Reform Required for Optimizing Patient and Health System Net Benefit in Australia. Appl Health Econ Health Policy. abril de 2018;16(2):153-6.

Herzog S, Shanahan M, Grimison P, Tran A, Wong N, Lintzeris N, et al. Systematic Review of the Costs and Benefits of Prescribed Cannabis-Based Medicines for the Management of Chronic Illness: Lessons from Multiple Sclerosis. Pharmacoeconomics. enero de 2018;36(1):67-78.

Steinemann S, Galanis D, Nguyen T, Biffl W. Motor vehicle crash fatalaties and undercompensated care associated with legalization of marijuana. J Trauma Acute Care Surg. 2018;85(3):566-71.

Hill KP, Saxon AJ. The Role of Cannabis Legalization in the Opioid Crisis. JAMA Intern Med. 01 de 2018;178(5):679-80.

Chu Y-WL. Commentary on Sarvet et al. (2018): What do we still need to know about the impacts of medical marijuana laws in the United States? Addiction. junio de 2018;113(6):1017-8.

Caulkins JP, Bao Y, Davenport S, Fahli I, Guo Y, Kinnard K, et al. Big data on a big new market: Insights from Washington State's legal cannabis market. Int J Drug Policy. 2018;57:86-94.

Belackova V, Wilkins C. Consumer agency in cannabis supply - Exploring auto-regulatory documents of the cannabis social clubs in Spain. Int J Drug Policy. 2018;54:26-34.

2017

Vincent PC, Collins RL, Liu L, Yu J, De Leo JA, Earleywine M. The effects of perceived quality on behavioral economic demand for marijuana: A web-based experiment. Drug Alcohol Depend. 1 de enero de 2017;170:174-80.

van Ours JC. Data on cannabis use now that legalization is gaining momentum. Addiction. 2017;112(7):1138-40.

Smart R, Caulkins JP, Kilmer B, Davenport S, Midgette G. Variation in cannabis potency and prices in a newly legal market: evidence from 30 million cannabis sales in Washington state. Addiction. diciembre de 2017;112(12):2167-77.

McGinty EE, Niederdeppe J, Heley K, Barry CL. Public perceptions of arguments supporting and

opposing recreational marijuana legalization. Prev Med. junio de 2017;99:80-6.

Hunt P, Pacula RL. Early Impacts of Marijuana Legalization: An Evaluation of Prices in Colorado and Washington. J Prim Prev. junio de 2017;38(3):221-48.

Cronce JM, Bittinger JN, Di Lodovico CM, Liu J. Independent Versus Co-occurring Substance Use in Relation to Gambling Outcomes in Older Adolescents and Young Adults. J Adolesc Health. mayo de 2017;60(5):528-33.

Carlini BH. Potency increase, product development and marijuana marketing in times of legalization. Addiction. diciembre de 2017;112(12):2178-9.

Carliner H, Mauro PM, Brown QL, Shmulewitz D, Rahim-Juwel R, Sarvet AL, et al. The widening gender gap in marijuana use prevalence in the U.S. during a period of economic change, 2002-2014. Drug Alcohol Depend. 1 de enero de 2017;170:51-8.

Álvarez A, Gamella JF, Parra I. The legalization of cannabis derivatives in Spain: Hypothesis on a potential emerging market. Adicciones. 28 de junio de 2017;29(3):195-206.

2016

Williams J, van Ours JC, Grossman M. Attitudes to legalizing cannabis use. Health Econ. 2016;25(9):1201-16.

Pinkas J, Jabłoński P, Kidawa M, Wierzba W. Use of marijuana for medical purposes. Ann Agric Environ Med. septiembre de 2016;23(3):525-8.

Kalant H. A critique of cannabis legalization proposals in Canada. Int J Drug Policy. 2016;34:5-10.

Jensen EL, Roussell A. Field observations of the developing legal recreational cannabis economy in Washington State. Int J Drug Policy. 2016;33:96-101.

Hajizadeh M. Legalizing and Regulating Marijuana in Canada: Review of Potential Economic, Social, and Health Impacts. Int J Health Policy Manag. 25 de mayo de 2016;5(8):453-6.

Collier R. How will pot legalization affect medical marijuana? CMAJ. 9 de agosto de 2016;188(11):792-3.

2015

Ogrodnik M, Kopp P, Bongaerts X, Tecco JM. An economic analysis of different cannabis decriminalization scenarios. Psychiatr Danub. septiembre de 2015;27 Suppl 1:S309-314.